T. K. Tan

A locally administered single cycle influenza vaccine expressing a non-fusogenic stabilised haemagglutinin stimulates strong T-cell and neutralising antibody immunity

This paper develops a single-cycle influenza vaccine, CLEARFLU, that induces neutralising antibodies to haemagglutinin and T-cell responses, offering broad and strain-specific protection.

Analysis of emergent bivalent antibody binding identifies the molecular reach as a critical determinant of SARS-CoV-2 neutralisation potency

This paper develops a bivalent binding model to analyze how molecular reach affects SARS-CoV-2 neutralization potency across antibodies.

Integrated Organ Immunity: Antigen-specific CD4-T cell-derived IFN-γ induced by BCG imprints prolonged lung innate resistance against respiratory viruses

Multiviral Quartet Nanocages Elicit Broad Anti-Coronavirus Responses for Proactive Vaccinology

A vaccine candidate with polyprotein antigens displayed on nanocages induces neutralizing antibodies to multiple SARS-like coronaviruses.

Mosaic RBD nanoparticles protect against multiple sarbecovirus challenges in animal models

This study designs mosaic RBD nanoparticles to elicit antibodies against conserved sarbecovirus epitopes, showing broader protection against SARS-CoV-2 variants and animal sarbecoviruses in animal models.

The circadian clock component BMAL1 regulates SARS-CoV-2 entry and replication in lung epithelial cells

This study shows BMAL1 regulates ACE2 expression and SARS-CoV-2 entry in lung epithelial cells, with SR9009 reducing viral replication through circadian mechanisms.

Neutralization of SARS-CoV-2 by destruction of the prefusion Spike

This paper identifies CR3022 as a monoclonal antibody that neutralizes SARS-CoV-2 by destroying its prefusion Spike conformation, suggesting therapeutic potential.

A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses

This study develops a vaccine candidate using SpyCatcher technology to display the SARS-CoV-2 RBD, showing strong neutralizing antibody responses in mice and pigs.

A novel biparatopic antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy

The paper develops a biparatopic antibody-ACE2 fusion (89C8-ACE2) that effectively blocks SARS-CoV-2 infection in vitro and neutralizes authentic virus at low nanomolar concentrations.

Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient

This paper identifies an antibody, EY6A, from a convalescent patient that neutralizes SARS-CoV-2 and cross-reacts with SARS-CoV-1 by binding a conserved epitope on the Spike protein.

cGAMP loading enhances the immunogenicity of VLP vaccines

This study shows that incorporating cGAMP into virus-like particles (VLPs) enhances their immunogenicity, leading to stronger T cell responses and antibody titres against HIV and influenza viruses.

Broadly inhibiting anti-neuraminidase monoclonal antibodies induced by trivalent influenza vaccine and H7N9 infection in humans

This study identifies broadly reactive human monoclonal antibodies against N1 neuraminidase from vaccination and H7N9 infection, showing cross-inhibition of diverse N1 NAs and protective efficacy in mice.